PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical ...

Sanofi agreed to buy Blueprint Medicines, a U.S. pharmaceutical company that specializes in rare immunological diseases, for up to $9.5 billion in a deal that seeks to strengthen the French ...